Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that results from the Company’s previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal. The article, entitled, “Diazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial,” was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be found here.
Related news for (SLNO)
- Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
- Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
- Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
- Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025
- Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025